884 related articles for article (PubMed ID: 29880584)
1. Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia.
Santomasso BD; Park JH; Salloum D; Riviere I; Flynn J; Mead E; Halton E; Wang X; Senechal B; Purdon T; Cross JR; Liu H; Vachha B; Chen X; DeAngelis LM; Li D; Bernal Y; Gonen M; Wendel HG; Sadelain M; Brentjens RJ
Cancer Discov; 2018 Aug; 8(8):958-971. PubMed ID: 29880584
[TBL] [Abstract][Full Text] [Related]
2. Toxicity and effectiveness of CD19 CAR T therapy in children with high-burden central nervous system refractory B-ALL.
Tan Y; Pan J; Deng B; Ling Z; Song W; Xu J; Duan J; Wang Z; Yu X; Chang AH; Feng X
Cancer Immunol Immunother; 2021 Jul; 70(7):1979-1993. PubMed ID: 33416942
[TBL] [Abstract][Full Text] [Related]
3. Chimeric Antigen Receptor T Cell-Mediated Neurotoxicity in Nonhuman Primates.
Taraseviciute A; Tkachev V; Ponce R; Turtle CJ; Snyder JM; Liggitt HD; Myerson D; Gonzalez-Cuyar L; Baldessari A; English C; Yu A; Zheng H; Furlan SN; Hunt DJ; Hoglund V; Finney O; Brakke H; Blazar BR; Berger C; Riddell SR; Gardner R; Kean LS; Jensen MC
Cancer Discov; 2018 Jun; 8(6):750-763. PubMed ID: 29563103
[TBL] [Abstract][Full Text] [Related]
4. Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy.
Chou CK; Turtle CJ
Expert Opin Biol Ther; 2020 Jun; 20(6):653-664. PubMed ID: 32067497
[No Abstract] [Full Text] [Related]
5. Utility of a safety switch to abrogate CD19.CAR T-cell-associated neurotoxicity.
Foster MC; Savoldo B; Lau W; Rubinos C; Grover N; Armistead P; Coghill J; Hagan RS; Morrison K; Buchanan FB; Cheng C; Laing S; Ivanova A; West J; Foster A; Serody J; Dotti G
Blood; 2021 Jun; 137(23):3306-3309. PubMed ID: 33624095
[No Abstract] [Full Text] [Related]
6. CAR T-cell therapy-related neurotoxicity in paediatric acute lymphocytic leukaemia.
Tan AP
Pediatr Blood Cancer; 2020 Nov; 67(11):e28635. PubMed ID: 32770654
[TBL] [Abstract][Full Text] [Related]
7. CAR-T Cell Therapy-Related Neurotoxicity in Pediatric Acute Lymphoblastic Leukemia: Spectrum of Imaging Findings.
Tan AP
Pediatr Neurol; 2020 Oct; 111():51-58. PubMed ID: 32951662
[TBL] [Abstract][Full Text] [Related]
8. Influence of patient characteristics on chimeric antigen receptor T cell therapy in B-cell acute lymphoblastic leukemia.
An F; Wang H; Liu Z; Wu F; Zhang J; Tao Q; Li Y; Shen Y; Ruan Y; Zhang Q; Pan Y; Zhu W; Qin H; Wang Y; Fu Y; Feng Z; Zhai Z
Nat Commun; 2020 Nov; 11(1):5928. PubMed ID: 33230103
[TBL] [Abstract][Full Text] [Related]
9. Molecular monitoring of T-cell kinetics and migration in severe neurotoxicity after real-world CD19-specific chimeric antigen receptor T cell therapy.
Berger SC; Fehse B; Akyüz N; Geffken M; Wolschke C; Janson D; Gagelmann N; Luther M; Wichmann D; Frenzel C; Thayssen G; Alegiani A; Badbaran A; Zeschke S; Dierlamm J; Kröger N; Ayuk FA
Haematologica; 2023 Feb; 108(2):444-456. PubMed ID: 35950534
[TBL] [Abstract][Full Text] [Related]
10. Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic.
Bachanova V; Bishop MR; Dahi P; Dholaria B; Grupp SA; Hayes-Lattin B; Janakiram M; Maziarz RT; McGuirk JP; Nastoupil LJ; Oluwole OO; Perales MA; Porter DL; Riedell PA;
Biol Blood Marrow Transplant; 2020 Jul; 26(7):1239-1246. PubMed ID: 32298807
[TBL] [Abstract][Full Text] [Related]
11. Dual CD19/CD22 CAR T Cells Show Feasibility in Pediatric/Young Adult B-ALL.
Cancer Discov; 2021 Dec; 11(12):2958. PubMed ID: 34686527
[TBL] [Abstract][Full Text] [Related]
12. Neurotoxicity following CD19/CD28ζ CAR T-cells in children and young adults with B-cell malignancies.
Shalabi H; Martin S; Yates B; Wolters PL; Kaplan C; Smith H; Sesi CR; Jess J; Toledo-Tamula MA; Struemph K; Delbrook CP; Khan OI; Mackall CL; Lee DW; Shah NN
Neuro Oncol; 2022 Sep; 24(9):1584-1597. PubMed ID: 35148417
[TBL] [Abstract][Full Text] [Related]
13. Surface Proteomics Reveals CD72 as a Target for
Nix MA; Mandal K; Geng H; Paranjape N; Lin YT; Rivera JM; Marcoulis M; White KL; Whitman JD; Bapat SP; Parker KR; Ramirez J; Deucher A; Phojanokong P; Steri V; Fattahi F; Hann BC; Satpathy AT; Manglik A; Stieglitz E; Wiita AP
Cancer Discov; 2021 Aug; 11(8):2032-2049. PubMed ID: 33727310
[TBL] [Abstract][Full Text] [Related]
14. CAR-T cell: Toxicities issues: Mechanisms and clinical management.
Wallet F; Sesques P; Devic P; Levrard M; Ader F; Friggeri A; Bachy E
Bull Cancer; 2021 Oct; 108(10S):S117-S127. PubMed ID: 34920794
[TBL] [Abstract][Full Text] [Related]
15. The Mechanisms of Altered Blood-Brain Barrier Permeability in CD19 CAR T-Cell Recipients.
Pinto SN; Krenciute G
Int J Mol Sci; 2024 Jan; 25(1):. PubMed ID: 38203814
[TBL] [Abstract][Full Text] [Related]
16. Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma.
Strati P; Nastoupil LJ; Westin J; Fayad LE; Ahmed S; Fowler NH; Hagemeister FB; Lee HJ; Iyer SP; Nair R; Parmar S; Rodriguez MA; Samaniego F; Steiner RE; Wang M; Pinnix CC; Adkins S; Claussen CM; Martinez CS; Hawkins MC; Johnson NA; Singh P; Mistry HE; Horowitz S; George S; Feng L; Kebriaei P; Shpall EJ; Neelapu SS; Tummala S; Chi TL
Blood Adv; 2020 Aug; 4(16):3943-3951. PubMed ID: 32822484
[TBL] [Abstract][Full Text] [Related]
17. GFAP and NfL increase during neurotoxicity from high baseline levels in pediatric CD19-CAR T-cell patients.
Gust J; Rawlings-Rhea SD; Wilson AL; Tulberg NM; Sherman AL; Seidel KD; Wu QV; Park JR; Gardner RA; Annesley CE
Blood Adv; 2023 Mar; 7(6):1001-1010. PubMed ID: 36006611
[TBL] [Abstract][Full Text] [Related]
18. Augmenting anti-CD19 and anti-CD22 CAR T-cell function using PD-1-CD28 checkpoint fusion proteins.
Blaeschke F; Stenger D; Apfelbeck A; Cadilha BL; Benmebarek MR; Mahdawi J; Ortner E; Lepenies M; Habjan N; Rataj F; Willier S; Kaeuferle T; Majzner RG; Busch DH; Kobold S; Feuchtinger T
Blood Cancer J; 2021 Jun; 11(6):108. PubMed ID: 34088894
[No Abstract] [Full Text] [Related]
19. Description of neurotoxicity in a series of patients treated with CAR T-cell therapy.
Belin C; Devic P; Ayrignac X; Dos Santos A; Paix A; Sirven-Villaros L; Simard C; Lamure S; Gastinne T; Ursu R; Berger C; Platon L; Tessoulin B; Azoulay E; Wallet F; Thieblemont C; Bachy E; Cartron G; Laplaud DA; Carpentier AF
Sci Rep; 2020 Nov; 10(1):18997. PubMed ID: 33149178
[TBL] [Abstract][Full Text] [Related]
20. Central nervous system neurotoxicity associated with nelarabine in T-cell acute lymphoblastic leukemia.
Pehlivan UA; Gürkan E; Açar İH; Bıçakcı YK
J Oncol Pharm Pract; 2023 Jan; 29(1):246-251. PubMed ID: 35593112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]